Take Action: Urge Your Senators to Co-Sponsor the Personal Care Products Safety Act
The Endocrine Society is focusing on endocrine-disrupting chemicals (EDCs) for the month of August as part of our centennial calendar. We are using this month to raise awareness about EDC research, as well as the impact that EDCs have in our everyday lives. Currently, we are working with the Senate on bipartisan legislation known as the Personal Care Products Safety Act (S. 1014), and we need your help in encouraging your Senators to co-sponsor this legislation.
If passed, this bill would:
Require the FDA to review the safety of at least five cosmetic ingredients each year
Amend the Federal Food, Drug, and Cosmetic Act to allow the FDA to collect ingredients of products and prohibit distribution of a personal care product if it could cause serious adverse health consequences
Take Action: Joining our campaign is quick and easy. Click to access the campaign, and a pre-written letter will be provided for you. You will only need to either provide your email and member ID, OR enter your address information so that the system will send your message to the correct recipients.
Society Members Selected for CMS Clinical Committee Developing MIPS Measures
The Centers for Medicare and Medicaid Services (CMS) has selected Endocrine Society members Drs. Ronald Harris from Geisinger Health System and Ilona Lorincz from University of Pennsylvania Hospital to provide an endocrine perspective as they develop care episode and patient condition groups for use in the Merit-based Incentive Payment System (MIPS.) These groupings will be used as the basis of resource use measures for use in MIPS.
The objectives of the Clinical Committee are to define the episode triggers and episode windows for care episode and patient condition groups, and provide input on episode grouping algorithm and measure development approach.
The Society is actively working on behalf of our members to shape the new Medicare payment system to ensure that the role of the endocrinologist is accurately captured in all aspects of the program. A session at the Clinical Endocrinology Update, September 9 in Seattle, Washington, will provide attendees with an understanding of the new system in advance of implementation in 2017.
Society Releases New Tools for Turner Syndrome Care Transitions
The Endocrine Society has released a new toolkit to assist patients and physicians with pediatric-to-adult transitions of care for Turner Syndrome. This initiative was spearheaded by the Society along with representatives from the Hormone Health Network, Turner Syndrome Foundation, American College of Physicians, and the American Academy of Pediatrics. The toolkit includes a comprehensive approach to successfully managing these transitions, including the following resources:
Transition Readiness Assessment: An assessment tool for providers to identify gaps in self-care knowledge and skills.
Clinical Summary & Transfer Record: A form to ensure that all clinical information related to the patient’s condition is included in his or her medical record upon transfer to the adult practice.
Recommended Approach for Transitioning into Adult Practice: A resource to assist providers who plan to receive emerging adults with Turner Syndrome.
Dosing Standards for Estrogen: An overview of dosing strategies for patients with Turner Syndrome
Recommended Approach for Planning for Pediatric Practices: A guide for pediatricians who are preparing to transition their patients to an adult practice
Adult Care Recommendations for Screening & Assessment: A chart to inform the patient which provider should be responsible for conducting various screenings and assessments into adulthood
Copies of these resources, along with tools for type 1 diabetes and growth hormone deficiency, can be found at endocrinetransitions.org.
The Food and Drug Administration requires Amgen to provide safety updates to clinicians as part of the Prolia Risk Evaluation and Mitigation Strategy (REMS.) Prolia has the following serious risks:
Hypocalcemia may be exacerbated by the use of Prolia®.
Osteonecrosis of the jaw (ONJ) has been reported in patients receiving Prolia®.
Atypical low-energy or low trauma subtrochanteric and diaphyseal femoral fractures, which may be bilateral, have been reported in patients receiving Prolia®. Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area.
In a clinical trial, women with postmenopausal osteoporosis treated with Prolia® presented with serious infections, such as serious skin infection and endocarditis, leading to hospitalization more frequently than the placebo group.
In a clinical trial, women with postmenopausal osteoporosis treated with Prolia® presented with generalized epidermal and dermal adverse events at a significantly higher rate compared to the placebo group. These included dermatitis, eczema, and rashes.
Additional information can be found on the Prolia website.